Constulose (Lactulose)

Generic Name

Lactulose

Brand Names

Constulose, Enulose, Generlac, Kristalose

FDA approval date: July 30, 1966

Classification: Osmotic Laxative

Form: Powder, Solution

What is Constulose (Lactulose)?

For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

Approved To Treat

Liver Failure

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)

Enrollment Status: Recruiting

Publish Date: June 16, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: The purpose of this study is to see if lactulose can improve the effectiveness of immunotherapy in patients with advanced cancer.

Effects of Collagen Peptide on Intestinal Permeability Following an Acute Aspirin Challenge in Adults With Moderate GI Symptoms: a Double-blind, Placebo-controlled, Randomised Study.

Enrollment Status: Recruiting

Publish Date: May 27, 2026

Intervention Type: Dietary supplement

Study Phase: Not Applicable

Summary: The goal of this clinical trial is to evaluate the effects of 45 days daily administration of three different doses (2.5g, 5g, and 10g) of collagen peptide in healthy adults as compared to a Placebo on intestinal permeability following an acute aspirin challenge. The main question it aims to answer is change from Day 42 to Day 45 following an acute aspirin challenge (NSAID) between three different...

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis -A Pilot Randomised Controlled Trial.

Enrollment Status: Recruiting

Publish Date: May 22, 2026

Intervention Type: Drug, Biological

Study Phase: Not Applicable

Summary: Exogenous growth factor-mobilized bone marrow (BM) stem cells(G-CSF) and DARBEPOETIN use have shown a differential response in the management of decompensated cirrhosis (DC) with improved survival, CTP and MELD scores. This study was designed to evaluate potential clinical benefit of repeated cycles of granulocyte-colony stimulating factor (G-CSF) and DARBEPOETIN versus single cycle on delta chang...

View All Clinical Trials